BRPI0606934A2 - Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado - Google Patents

Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado

Info

Publication number
BRPI0606934A2
BRPI0606934A2 BRPI0606934A BRPI0606934A BRPI0606934A2 BR PI0606934 A2 BRPI0606934 A2 BR PI0606934A2 BR PI0606934 A BRPI0606934 A BR PI0606934A BR PI0606934 A BRPI0606934 A BR PI0606934A BR PI0606934 A2 BRPI0606934 A2 BR PI0606934A2
Authority
BR
Brazil
Prior art keywords
biologically active
life
protein conjugate
polypeptide
active protein
Prior art date
Application number
BRPI0606934A
Other languages
English (en)
Inventor
Besman Marc
Chipman Stewart
Leung David
Singer Jack
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of BRPI0606934A2 publication Critical patent/BRPI0606934A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

CONJUGADO DE PROTEÍNA BIOLOGICAMENTE ATIVA, COMPOSIÇÃO, MOLÉCULA DE DNA QUIMÉRICA, VETOR, CÉLULA, E, MÉTODOS PARA PREPARAR CONJUGADO DE PROTEÍNA BIOLOGICAMENTE ATIVA, E PARA DETERMINAR SE UM DADO CONJUGADO DE PROTEÍNA EXIBE UMA MEIA-VIDA DE PLASMA MODIFICADA COMPARADA COM A MEIA-VIDA INTRÍNSECA DO POLIPEPTÍDEO BIOLOGICAMENTE ATIVO NÃO CONJUGADO. São descritos conjugados de proteína biologicamente ativa que compreendem um polipeptídeo biologicamente ativo copulado via uma ligação peptídica em um polipeptídeo compreendendo de 2 a cerca de 500 unidades de um motivo de peptídeo repetitivo, no qual o conjugado de proteina biologicamente ativa exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca da proteína ou do polipeptídeo biologicamente ativa(o) não-conjugada(o). Também são descritos métodos de preparar e usar as proteínas conjugadas, bem como métodos para determinar se um dado conjugado exibe uma meia-vida modificada relativa à meia-vida intrínseca do polipeptídeo não-conjugado.
BRPI0606934A 2005-01-25 2006-01-25 Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado BRPI0606934A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64711905P 2005-01-25 2005-01-25
US71258505P 2005-08-30 2005-08-30
PCT/US2006/002501 WO2006081249A2 (en) 2005-01-25 2006-01-25 Conjugates of biologically active proteins having a modified in vivo half-life

Publications (1)

Publication Number Publication Date
BRPI0606934A2 true BRPI0606934A2 (pt) 2017-07-11

Family

ID=36644921

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606934A BRPI0606934A2 (pt) 2005-01-25 2006-01-25 Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado

Country Status (14)

Country Link
US (2) US8129348B2 (pt)
EP (1) EP1841787A2 (pt)
JP (2) JP5735194B2 (pt)
KR (1) KR101608083B1 (pt)
CN (1) CN103172747A (pt)
AU (1) AU2006208199B2 (pt)
BR (1) BRPI0606934A2 (pt)
CA (1) CA2595695A1 (pt)
IL (1) IL184763A (pt)
MX (1) MX2007008982A (pt)
NO (1) NO20074267L (pt)
NZ (1) NZ556726A (pt)
RU (1) RU2007132188A (pt)
WO (1) WO2006081249A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996937A4 (en) † 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
ES2529315T5 (es) † 2006-03-06 2024-02-23 Amunix Operating Inc Polímeros recombinantes no estructurados y usos de los mismos
EP2009103A1 (en) 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
DK2173890T3 (da) 2007-06-21 2011-06-27 Univ Muenchen Tech Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro
AU2013203326B2 (en) * 2007-06-21 2013-08-01 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
CN101939329A (zh) * 2007-08-30 2011-01-05 滑铁卢大学 以氨基酸配对为基础的自组装肽和方法
EA201101015A1 (ru) 2008-12-29 2012-02-28 Лонца Брен Са Способ получения бивалирудина
JP5499296B2 (ja) * 2009-02-03 2014-05-21 国立大学法人東京農工大学 細胞の吸着を制御可能なポリペプチド
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
PT2440228T (pt) 2009-06-08 2018-12-24 Amunix Operating Inc Polipéptidos de regulação da glicose e métodos de preparação e utilização dos mesmos
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
WO2011144756A1 (en) 2010-05-21 2011-11-24 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
CA2864904C (en) 2012-02-15 2023-04-25 Amunix Operating Inc. Factor viii compositions and methods of making and using same
EP3549953A1 (en) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
CN107496932A (zh) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
NZ701573A (en) 2012-05-17 2017-04-28 Extend Biosciences Inc Carriers for improved drug delivery
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3256585A4 (en) 2015-02-13 2018-08-15 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN104988107B (zh) * 2015-05-19 2018-06-08 中国农业科学院兰州兽医研究所 一种高效表达口蹄疫病毒抗原基因的重组乳酸杆菌及其制备方法和应用
EP3303380B1 (en) * 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
IL307276A (en) 2015-08-28 2023-11-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
KR102613874B1 (ko) 2017-01-30 2023-12-15 알렉시온 파마슈티칼스, 인코포레이티드 1가 항-프로페르딘 항체 및 항체 단편
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US20220370546A1 (en) * 2019-11-05 2022-11-24 Kyoto University Peptide, composition, and method for treating, preventing, or ameliorating mood disorder
CN112608366A (zh) * 2020-12-31 2021-04-06 中国药科大学 超正电荷聚多肽及其制备方法、应用
CN113480667B (zh) * 2021-08-17 2023-03-28 长春萤火虫生物科技有限公司 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用
WO2024128079A1 (ja) * 2022-12-16 2024-06-20 東亞合成株式会社 合成ペプチド及び構築物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
AU648020B2 (en) 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6455678B1 (en) 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
CN1240479A (zh) * 1996-07-09 2000-01-05 安姆根有限公司 截短的可溶性肿瘤坏死因子i－型和ii－型受体
WO1998049198A1 (en) * 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
ES2341217T3 (es) 1999-01-19 2010-06-17 Maxygen, Inc. Recombinacion de acidos nucleicos mediada por oligonucleotidos.
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
AU2001267337A1 (en) * 2000-06-30 2002-01-14 Maxygen Aps Peptide extended glycosylated polypeptides
EP1497331A2 (en) 2002-01-14 2005-01-19 William Herman Multispecific binding molecules
CN100472488C (zh) 2004-07-06 2009-03-25 株式会社Ntt都科摩 消息发送系统和消息发送方法
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
CN101111516B (zh) * 2005-01-25 2013-02-27 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life

Also Published As

Publication number Publication date
IL184763A (en) 2013-05-30
US20120252717A1 (en) 2012-10-04
WO2006081249A2 (en) 2006-08-03
IL184763A0 (en) 2007-12-03
MX2007008982A (es) 2007-12-06
RU2007132188A (ru) 2009-03-10
US8129348B2 (en) 2012-03-06
NZ556726A (en) 2011-04-29
AU2006208199B2 (en) 2012-06-07
WO2006081249A8 (en) 2007-09-13
US8748577B2 (en) 2014-06-10
AU2006208199A1 (en) 2006-08-03
NO20074267L (no) 2007-09-28
KR101608083B1 (ko) 2016-04-01
WO2006081249A3 (en) 2007-02-01
JP2008528002A (ja) 2008-07-31
KR20070119622A (ko) 2007-12-20
EP1841787A2 (en) 2007-10-10
JP5735194B2 (ja) 2015-06-17
WO2006081249A9 (en) 2007-07-26
JP2013100292A (ja) 2013-05-23
CA2595695A1 (en) 2006-08-03
CN103172747A (zh) 2013-06-26
US20090298762A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
BRPI0606934A2 (pt) Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
DE602006020617D1 (de) Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
PE20060880A1 (es) Conjugados de polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
BRPI0607988A2 (pt) composto, composição farmacêutica, e método para induzir apoptose em uma célula
DE602006017667D1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2006031811A3 (en) Glycopegylated interferon alpha
WO2007106120A3 (en) Serum albumin binding peptides for tumor targeting
WO2003037172A3 (en) Endothelial-cell binding peptides for diagnosis and therapy
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
WO2008011633A3 (en) Glycosylation of peptides via o-linked glycosylation sequences
WO2006114308A8 (de) Carrier zum targeting von nervenzellen
NO20080970L (no) Glykopegylert faktor VII og faktor VIIA
WO2006050930A3 (en) Conjugates with enhanced cell uptake activity
WO2005090395A3 (en) Methods for increasing protein polyethylene glycol (peg) conjugation
EA201100071A1 (ru) Новые композиции и способы
ATE306498T1 (de) Von zellen präsentierte peptide
ATE520025T1 (de) Test für morbus-parkinson-therapeutika
WO2009005579A9 (en) High affinity fluorochrome binding peptides
CN108271373B (zh) 蛋白酶抗性脂化glp-1类似物
ATE529445T1 (de) Biokinetik zur schnellen beseitigung von polypeptiden
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law
B11O Dismissal: republication [chapter 11.15 patent gazette]

Free format text: O DESPACHO PUBLICADO NA RPI 2093 DE 15/02/2011 REFERE-SE A PETICAO 20070101765/RJ DE 24/07/2007.

B11M Decision cancelled [chapter 11.13 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]